Esteban S. Masuda

Rigel (United States) — United States

Immunology and Microbiology · Life Sciences

36h-index3.8kcitations114works4.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Mast cells and histamine(27), Immune Cell Function and Interaction(12), Cytokine Signaling Pathways and Interactions(12), Immune Response and Inflammation(11), Monoclonal and Polyclonal Antibodies Research(11)

Publications114 total

Clonal hematopoiesis-related mutant ASXL1 promotes atherosclerosis in mice via dysregulated innate immunity
Nature Cardiovascular Research·2024· 13 cited
51240 R209, A Skin Penetrant IRAK1 and IRAK4 Inhibitor for Topical Indications
Journal of the American Academy of Dermatology·2024
CH-related Mutant ASXL1 Promotes Atherosclerosis in Mice via Dysregulated Innate Immunity
2024Open Access
Tuning the Reactivity of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Optimal <i>in Vivo</i> Efficacy
ACS Medicinal Chemistry Letters·2023· 4 citedOpen Access
Long-Term Treatment with Fostamatinib in Japanese Patients with Primary Immune Thrombocytopenia: An Open-Label Extension Study Following a Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group Study
Blood·2023Open Access
LONG-TERM SAFETY PROFILE OF THE ORAL SPLEEN TYROSINE KINASE INHIBITOR FOSTAMATINIB IN IMMUNE THROMBOCYTOPENIA (ITP) AND OTHER DISEASES
Hematology Transfusion and Cell Therapy·2023· 1 citedOpen Access
Randomized Trial on the Effect of an Oral Spleen Tyrosine Kinase Inhibitor in the Treatment of IgA Nephropathy
Kidney International Reports·2023· 17 citedOpen Access
Regulation of bone homeostasis by MERTK and TYRO3
Nature Communications·2022· 35 citedOpen Access
SYK Kinase As a Master Regulator of Netosis
Blood·2022· 1 cited
Fostamatinib for the Treatment of Japanese Patients with Primary Immune Thrombocytopenia: A Phase 3, Placebo-Controlled, Double-Blind, Parallel-Group Study
Blood·2022· 2 cited
Optimization of Pyrimidine Compounds as Potent JAK1 Inhibitors and the Discovery of R507 as a Clinical Candidate
ACS Medicinal Chemistry Letters·2022· 3 citedOpen Access
Syk Activation in Circulating and Tissue Innate Immune Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Arthritis & Rheumatology·2022· 17 citedOpen Access
Bicyclic pyrimidine compounds as potent IRAK4 inhibitors
Bioorganic & Medicinal Chemistry Letters·2022· 2 citedOpen Access
Discovery of 5-Aryl-2,4-diaminopyrimidine Compounds as Potent and Selective IRAK4 Inhibitors
ACS Medicinal Chemistry Letters·2022· 10 citedOpen Access
Inhibition of spleen tyrosine kinase decreases donor specific antibody levels in a rat model of sensitization
Scientific Reports·2022· 9 citedOpen Access
Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors
Nature Communications·2022· 23 citedOpen Access
Eradicating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors
Research Square (Research Square)·2021Open Access
Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib
Therapeutic Advances in Hematology·2021· 60 citedOpen Access
Long-Term Safety Profile of the Oral Spleen Tyrosine Kinase Inhibitor Fostamatinib in Immune Thrombocytopenia (ITP) and Other Diseases
Blood·2020· 36 cited
Clinical Trial to Evaluate an Approved ITP Therapy Targeting Spleen Tyrosine Kinase (SYK) for Prevention and Treatment of COVID-19 Related Complications
Blood·2020· 2 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Naoko Arai(14), Donald G. Payan(11), Ken‐ichi Arai(6), Akio Tsuboi(6), Vanessa Taylor(5), Hiroshi Tokumitsu(5), Ryu Imamura(5), Charles D. Pusey(5), H. Zhao(4), Elliott B. Grossbard(4), Yoshiyuki Naito(4), Richard H. Scheller(4), Ken‐ichi Arai(4), Mark K. Bennett(4), Susan M. Molineaux(4), John McDaid(4), Frederick W.K. Tam(4), Stephen P. McAdoo(4), Betty Huang(4), Ellen Herlaar(3)